This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lynch, S. G Articles by LeVine, S. M Search for Related Content PubMed Articles by Lynch, S. G Articles by LeVine, S. M Social Bookmarking                         What's this?

Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study

Departments of Neurology

Kathy Peters

Departments of Neurology

Steven M LeVine

Physiology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas, 66160, USA

Chronic progressive Multiple Sclerosis is refractory to many conventional treatments. We performed a pilot study testing desferoxamine (DFO) as a candidate in the treatment of chronic progressive Multiple Sclerosis. DFO was given daily by 8 h subcutaneous infusions at a dose of 2 grams daily for 7 days, followed by 1 gram daily for 7 days. Eighteen of 19 individuals completed the full dose of 21 grams. One patient was unable to complete the course due to nausea. No acute deterioration of neurological status was seen during the administration of DFO. No worsening of vision or hearing was noted except that the one patient who was unable to tolerate the medication had a transient reduction in hearing. All patients had a local redness at the injection site. None of the patients had any sudden worsening during or shortly after the treatment This pilot study suggests that DFO is relatively well tolerated by Multiple Sclerosis patients when given in a short course of therapy.

Key Words: Multiple Sclerosis • desferoxamine • free radicals • iron • chelation

Multiple Sclerosis, Vol. 2, No. 3, 157-160 (1996)
DOI: 10.1177/135245859600200306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S A Schneider, J Hardy, and K P Bhatia Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential? J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 589 - 590. [Full Text] [PDF]

				K.M. Mitchell, A.L. Dotson, K.M. Cool, A. Chakrabarty, S.H. Benedict, and S.M. LeVine Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis Multiple Sclerosis, November 1, 2007; 13(9): 1118 - 1126. [Abstract] [PDF]

				C. Sfagos, A. C Makis, A. Chaidos, E. C Hatzimichael, A. Dalamaga, K. Kosma, and K. L. Bourantas Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients Multiple Sclerosis, June 1, 2005; 11(3): 272 - 275. [Abstract] [PDF]

				A Chakrabarty, M R Emerson, and S M LeVine Hemeoxygenase-1 in SJL mice with experimental allergic encephalomyelitis Multiple Sclerosis, August 1, 2003; 9(4): 372 - 381. [Abstract] [PDF]